The following study, incorporating data from six trials with 49,875 participants assessing four SGLT2 inhibitors, revealed a reduction in serious hyperkalemia risk (1754 cases) with a hazard ratio of 0.84 (95% CI, 0.76-0.93). The gene discussed is SLC5A2; the disease is Hyperkalemia.